A5000204204- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Head and Neck Cancer Studies
- Colorectal Cancer Treatments and Studies
- CAR-T cell therapy research
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Research Studies
- Statistical Methods in Clinical Trials
- Genetic factors in colorectal cancer
- PI3K/AKT/mTOR signaling in cancer
- Chronic Lymphocytic Leukemia Research
- Cancer Treatment and Pharmacology
- Health Systems, Economic Evaluations, Quality of Life
- Lymphoma Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Gastric Cancer Management and Outcomes
- PARP inhibition in cancer therapy
- Epigenetics and DNA Methylation
- Radiomics and Machine Learning in Medical Imaging
- HER2/EGFR in Cancer Research
- Neuroendocrine Tumor Research Advances
- Molecular Biology Techniques and Applications
- Tumors and Oncological Cases
- Head and Neck Surgical Oncology
Princess Margaret Cancer Centre
2016-2025
University Health Network
2016-2025
University of Toronto
2016-2025
Loma Linda University
2024
Weatherford College
2008-2022
National Cancer Centre Japan
2022
Health Net
2017-2021
American Association For Cancer Research
2021
Institut Claudius Regaud
2018
Hôpital René Huguenin
2018
The AACR Project GENIE is an international data-sharing consortium focused on generating evidence base for precision cancer medicine by integrating clinical-grade genomic data with clinical outcome tens of thousands patients treated at multiple institutions worldwide. In conjunction the first public release from approximately 19,000 samples, we describe goals, structure, and standards report conclusions high-level analysis initial phase data. We also provide examples utility data, such as...
PURPOSE: To assess the feasibility of administering OSI-774, to recommend a dose on protracted, continuous daily schedule, characterize its pharmacokinetic behavior, and acquire preliminary evidence anticancer activity. PATIENTS AND METHODS: Patients with advanced solid malignancies were treated escalating doses OSI-774 in three study parts (A C) evaluate progressively longer treatment intervals. Part A patients received 25 100 mg once daily, for 3 days each week, weeks every 4 weeks. B...
To determine the efficacy and safety profiles of erlotinib in patients with advanced recurrent and/or metastatic squamous cell cancer head neck (HNSCC).Patients locally HNSCC, regardless their HER1/EGFR status, were treated at an initial dose 150 mg daily. Dose reductions or escalations allowed based on tolerability erlotinib.One-hundred fifteen enrolled onto this study. Forty-seven percent received daily throughout entire study, 6% had escalations, 46% required interruptions. Five achieved...
To define human papillomavirus (HPV) -positive oropharyngeal cancers (OPC) suitable for treatment deintensification according to low risk of distant metastasis (DM).OPC treated with radiotherapy (RT) or chemoradiotherapy (CRT) from 2001 2009 were included. Outcomes compared HPV-positive versus HPV-negative patients. Univariate and multivariate analyses identified outcome predictors. Recursive partitioning analysis (RPA) stratified the DM risk.HPV status was ascertained in 505 (56%) 899...
This randomized study compared the results achieved by concurrent chemoradiotherapy (CRT) versus radiotherapy (RT) alone for nasopharyngeal carcinoma (NPC) with advanced nodal disease.Patients nonkeratinizing/undifferentiated NPC staged T1-4N2-3M0 were to CRT or RT. Both arms treated same RT technique and dose fractionation. The patients given cisplatin 100 mg/m2 on days 1, 22, 43, followed 80 fluorouracil 1,000 mg/m2/d 96 hours starting 71, 99, 127.From 1999 January 2004, 348 eligible...
Purpose To refine stage and prognostic group for human papillomavirus (HPV) –related nonmetastatic (M0) oropharyngeal cancer (OPC). Methods All patients with p16-confirmed OPC treated radiotherapy or without chemotherapy from 2000 to 2010 were included. Overall survival (OS) was compared among TNM stages HPV-related HPV-unrelated separately. For OPC, recursive partitioning analysis (RPA) derived new RPA objectively. Cox regression used calculate adjusted hazard ratios (AHRs) derive AHR...
Standard cytotoxic treatments for neuroendocrine tumours have been associated with limited activity and remarkable toxicity. A phase II study was designed to evaluate the efficacy, safety pharmacodynamics of temsirolimus in patients advanced carcinoma (NEC). Thirty-seven progressive NEC received intravenous weekly doses 25 mg temsirolimus. Patients were evaluated tumour response, time progression (TTP), overall survival (OS) adverse events (AE). Twenty-two archival specimens, as well 13...
A significant proportion of oropharyngeal squamous cell carcinomas (OSCC) are associated with the human papilloma virus (HPV), particularly HPV16. The optimal method for HPV determination on archival materials however, remains unclear. We compared a quantitative real-time polymerase chain reaction (qRT-PCR) assay HPV16 mRNA to DNA in situ hybridization (ISH) method, and evaluated their significance overall (OS) disease-free (DFS) survival.Matched, biopsies from 111 patients OSCC were using...
Neuroendocrine tumors (NETs) arise from a variety of anatomic sites and share the capacity for production hormones vasoactive peptides. Because their perceived rarity, NETs have not historically been focus rigorous clinical research. However, diagnosed incidence has increasing, estimated prevalence in United States exceeds 100,000 individuals. The recent completion several phase III studies, including those evaluating octreotide, sunitinib, everolimus, demonstrated that evaluation novel...
<h3>Importance</h3> Dual blockade of programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) may overcome immune checkpoint inhibition. It is unknown whether dual can potentiate antitumor activity without compromising safety in patients with recurrent or metastatic head neck squamous cell carcinoma (R/M HNSCC) low no PD-L1 tumor expression. <h3>Objective</h3> To assess objective response rate durvalumab combined tremelimumab. <h3>Design, Setting,...
The clinical utility of molecular profiling tumor tissue to guide treatment patients with advanced solid tumors is unknown. Our objectives were evaluate the frequency genomic alterations, "actionability" somatic variants, enrollment in mutation-targeted or other trials, and outcome for at Princess Margaret Cancer Centre (PM). Patients aged ≥18 years, good performance status, archival available prospectively consented. DNA from formalin-fixed paraffin-embedded was tested using a MALDI-TOF MS...
Birabresib (MK-8628/OTX015) is a first-in-class bromodomain inhibitor with activity in select hematologic tumors. Safety, efficacy, and pharmacokinetics of birabresib were evaluated patients castrate-resistant prostate cancer, nuclear protein testis midline carcinoma (NMC), non-small-cell lung cancer this phase Ib study.Forty-seven enrolled to receive once daily at starting doses 80 mg continuously (cohort A) or 100 for 7 consecutive days B) 21-day cycles using parallel dose escalation 3 +...
BackgroundPatients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) progressing on platinum-based chemotherapy have poor prognoses limited therapeutic options. Programmed death-1 (PD-1) its ligand 1 (PD-L1) are frequently upregulated in HNSCC. The international, multi-institutional, single-arm, phase II HAWK study (NCT02207530) evaluated durvalumab monotherapy, an anti-PD-L1 monoclonal antibody, PD-L1-high patients platinum-refractory R/M HNSCC.Patients...